Connexin-purinergic signaling in enteric glia mediates the prolonged effect of morphine on constipation

Sukhada Bhave1, Aravind Gade1, Minho Kang1

  • 1Department of Pharmacology and Toxicology, Virginia Commonwealth University, Richmond, Virginia, USA.

Insights

Prolonged morphine use causes gut inflammation and constipation by activating enteric glia. Blocking connexin-purinergic signaling with carbenoxolone reduces these side effects, offering potential therapeutic strategies.

Area of Science:

  • Neuroscience
  • Gastroenterology
  • Pharmacology

Background:

  • Morphine is a key pain reliever but causes side effects like constipation and inflammation.
  • These side effects are linked to gut barrier dysfunction, microbial imbalance, and bacterial translocation.
  • Enteric glia's role in morphine-induced inflammation and constipation is not fully understood.

Purpose of the Study:

  • To investigate the role of enteric glia in mediating inflammation and constipation from prolonged morphine treatment.
  • To explore the involvement of purinergic signaling and connexin 43 (Cx43) in enteric glia responses to morphine and bacterial products.

Main Methods:

  • Isolated enteric glia from mice with long-term morphine treatment for in vivo and in vitro analysis.
  • Assessed purinergic P2X receptor activity, ATP-induced currents, and inflammatory gene expression (IL6, IL-1β).
  • Investigated the effect of lipopolysaccharide (LPS) and Cx43 blockers (Gap26, carbenoxolone) on glia and colonic inflammation.

Main Results:

  • Long-term morphine treatment enhanced purinergic P2X receptor activity in enteric glia.
  • LPS increased P2X currents, IL6, IL-1β mRNA, and Cx43 expression in enteric glia, enhancing ATP release.
  • Carbenoxolone significantly reduced morphine-induced colonic inflammation, gut wall disruption, and constipation.

Conclusions:

  • Enteric glia activation, mediated by connexin-purinergic signaling, plays a crucial role in morphine-induced gut inflammation and constipation.
  • Targeting Cx43-dependent purinergic signaling in enteric glia may offer a therapeutic approach to mitigate morphine's adverse gastrointestinal effects.

Related Concept Videos

Drugs Affecting GI Tract Motility: Opioids as Antidiarrheal Agents01:17

Drugs Affecting GI Tract Motility: Opioids as Antidiarrheal Agents

Diarrhea, a condition marked by frequent loose or watery bowel movements, can be triggered by multiple factors such as viral or bacterial infections, food intolerances, anxiety, medications, and digestive disorders. Symptoms may include abdominal pain, bloating, nausea, and cramping. Severe or prolonged diarrhea can lead to complications like electrolyte imbalances, malnutrition, and dehydration if left untreated.
Opioids, widely used antidiarrheal agents, mitigate diarrhea by slowing down...
778
Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists01:23

Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists

Serotonin, a crucial neurotransmitter synthesized by enterochromaffin cells, plays a cardinal role in regulating gastrointestinal (GI) motility. With over 90% of the body's total serotonin in the GI tract, its influence on digestive processes is profound. Serotonin is swiftly released upon various stimuli, such as food boluses or certain drugs, triggering intrinsic sensory neurons in the myenteric plexus and extrinsic vagal and spinal sensory neurons. This leads to the activation of the...
1.1K
Drugs for Treatment of Constipation-Predominant IBS01:21

Drugs for Treatment of Constipation-Predominant IBS

Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
1.0K
Analgesia and Pain Management01:25

Analgesia and Pain Management

Pain is critical to various clinical pathologies, provoking an urgent need for effective management. Pain, whether acute or chronic, is a complex neurochemical process. Its alleviation depends on the type, with nonopioid analgesics effective for mild to moderate pain, such as musculoskeletal or inflammatory pain, while neuropathic pain responds best to anticonvulsants, tricyclic antidepressants, or serotonin/norepinephrine reuptake inhibitors. For severe acute or chronic pain, opioids may be...
2.5K
Drugs Affecting GI Tract Motility: Bulk-Forming and Stimulant Laxatives01:22

Drugs Affecting GI Tract Motility: Bulk-Forming and Stimulant Laxatives

Laxatives enhance bowel movements and alleviate constipation. They augment the stool's bulk, stimulate intestinal muscle contractions, draw water into the intestines, or soften the stool. There are five key types of laxatives: bulk laxatives, stimulant laxatives, osmotic laxatives, stool softeners, and lubricant laxatives.
Bulk-forming laxatives, such as psyllium, methylcellulose, and polycarbophil, absorb water in the intestine, increasing stool bulk and promoting bowel movement. This...
664
Drugs Affecting GI Tract Motility: Other Laxatives01:20

Drugs Affecting GI Tract Motility: Other Laxatives

Laxatives are primarily used to alleviate constipation, a common gastrointestinal disorder characterized by infrequent bowel movements and difficulty passing stools. They work by various mechanisms to increase the volume or frequency of bowel movements. The primary modes of action of laxatives include increasing stool bulk, softening the stool, stimulating intestinal motility, and osmotically drawing water into the intestines.
Osmotic or saline laxatives, like magnesium hydroxide or milk of...
1.3K